• email inquiry@market.us
  • phone+1 718 618 4351 (International)
  • phone+91 78878 22626 (Asia)
menu logo logo
more_vert
  • About Us
  • Contact Us
  • Our Team
  • Privacy Policy
July 30, 2019

Home / Pfizer is going to Combine its Off-Patent Drug Business with Mylan

Pfizer is going to Combine its Off-Patent Drug Business with Mylan

Tajammul Pangarkar

Last updated on:July 30, 2019 Market.us

World’s Largest Drug manufacturer Pfizer today announced that they are going to combine the off-patent drug business with Mylan. Mylan is a famous Generic Drugmaker company based in the United States. As per the merger terms, the deal is an all-stock deal, which means each Mylan share would be converted into the stock of a newly formed company. The ratio of holding is 57:43, hence the Pfizer shareholders will have 57% of the shares, and Mylan shareholders will have 43% shares in a new company.

After the merger of off-patent business with Mylan, the new company will be formed. The new company will sell Mylan’s EpiPen and Pfizer’s Viagra drugs in the United States. These two drugs are the most popular in the United States. With this merger of two businesses, the newly formed company could handle the revenue of nearly $20 billion. In 2018, Mylan had the receipt of $11.5 billion. But, Pfizer has not revealed the earnings reports yet. Mylan was in a little trouble with United States authorities, as the inquiry is ongoing on EpiPens increased prices in the market.

Amidst this issue, Mylan formed a strategic review committee last year, which helped the company to decide the future moves. Last year, Pfizer combined the consumer-health business with GlaxoSmithKline’s joint venture. In the joint-venture, GlaxoSmithKline has the controlling stake. The same way, Pfizer is taking controlling stake in the merger as it has 57% of the stocks. Pfizer’s Michael Goettler would lead the newly formed company, with Mylan Chairman Robert Coury as Executive Chairman, and Mylan CEO Heather Bresch would leave the business. CEO Heather Bresch faced a lot of controversies when the company increased the prices of Life-saving EpiPen drug for patients with extreme allergy conditions. According to Jared Holz, health-care strategist at Jefferies firm, the change in management will bring a positive impact on the business.

Tajammul Pangarkar

Tajammul Pangarkar is a tech blogger, and has contributed to numerous tech magazines. Tajammul longstanding experience in the field of mobile technology and industry research is reflected in his insightful news articles as presented on News.market.us. His interest lies in understanding the tech trends, mobile applications and technical consciousness on these increasingly consumer-oriented industries. When he is not ruminating about the tech world, he can be found playing table tennis or hanging out with his friends.

Share this post:

Share on Facebook Share on Twitter Share on LinkedIn Share on Email

  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 618 4351 (International)
  • phone+91 78878 22626 (Asia)
  • emailinquiry@market.us

Find Help

  • Contact Us

Legal

  • Privacy Policy
  • Our Team

Explore

  • Business
  • Technology
  • Health
  • Science

Secured Payment Options

PayPal Payment System
Payoneer Payment System

© 2022 Market.us. All Rights Reserved.